![conference banner](/images/conference-banner.jpeg)
Abstract
Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. In addition to their antiresorptive effects, preclinical evidence strongly suggests that N-BPs have anticancer activity. Some of the activities associated with N-BPs are observed in human γδ T cells that straddle the interface of innate and adaptive immunity and have potent anti-tumour activity. This review examines the molecular and cellular mechanisms through which N-BPs stimulate the expansion and cytotoxic activity of human γδ T cells. In addition, we discuss the emerging clinical evidence that N-BPs have a role in cancer immunotherapy.
Keywords: Bisphosphonate, zoledronate, IPP, gamma delta T cell, immunotherapy, cancer, Cancer Immunotherapy, nitrogen-containing bisphosphonates (N-BPs), osteoclast-mediated bone resorption, sorptive effects, T cells, mevalonate path-way, isoprenoid lipids, farnesyl pyrophosphate synthase (FPPS), GTPases, monocytes, macrophages, endothelial, tumour cells, adaptive immunity, Innate immunity, macro-phages, antigen-targeted cytotoxic cells, histocompatibil-ity complex (MHC), farnesyl pyrophosphate (FPP), tumour antigen, phosphoantigens, cytokines, Tregs' activity, pa-midronate, risedronate, immunostimulatory properties, antigen-presenting cells, peripheral blood mononuclear cells (PBMC), putative antigen-presenting molecule, nonhuman antigen-presenting, cytolytic granules, anti-tumour activity, chronic myelogenous leukemic cells, autologous, kemia cells, allogeneic, zoledronate-treated, myeloid leukemia, CANCER IMMUNO-THERAPY, antigen-recognition properties, a synthetic phosphoantigen, pleiotropic pharmaceutical agents, tumor-hostile counterpart, goserelin, tamoxifen, anastrozole, endocrine-responsive, multichemotherapy, chemorefractory adrenocortical carcinoma
Current Pharmaceutical Design
Title: Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy
Volume: 16 Issue: 27
Author(s): P. Clezardin and M. Massaia
Affiliation:
Keywords: Bisphosphonate, zoledronate, IPP, gamma delta T cell, immunotherapy, cancer, Cancer Immunotherapy, nitrogen-containing bisphosphonates (N-BPs), osteoclast-mediated bone resorption, sorptive effects, T cells, mevalonate path-way, isoprenoid lipids, farnesyl pyrophosphate synthase (FPPS), GTPases, monocytes, macrophages, endothelial, tumour cells, adaptive immunity, Innate immunity, macro-phages, antigen-targeted cytotoxic cells, histocompatibil-ity complex (MHC), farnesyl pyrophosphate (FPP), tumour antigen, phosphoantigens, cytokines, Tregs' activity, pa-midronate, risedronate, immunostimulatory properties, antigen-presenting cells, peripheral blood mononuclear cells (PBMC), putative antigen-presenting molecule, nonhuman antigen-presenting, cytolytic granules, anti-tumour activity, chronic myelogenous leukemic cells, autologous, kemia cells, allogeneic, zoledronate-treated, myeloid leukemia, CANCER IMMUNO-THERAPY, antigen-recognition properties, a synthetic phosphoantigen, pleiotropic pharmaceutical agents, tumor-hostile counterpart, goserelin, tamoxifen, anastrozole, endocrine-responsive, multichemotherapy, chemorefractory adrenocortical carcinoma
Abstract: Bisphosphonates, especially nitrogen-containing bisphosphonates (N-BPs), are widely used to block bone destruction in cancer patients with bone metastasis because they are effective inhibitors of osteoclast-mediated bone resorption. In addition to their antiresorptive effects, preclinical evidence strongly suggests that N-BPs have anticancer activity. Some of the activities associated with N-BPs are observed in human γδ T cells that straddle the interface of innate and adaptive immunity and have potent anti-tumour activity. This review examines the molecular and cellular mechanisms through which N-BPs stimulate the expansion and cytotoxic activity of human γδ T cells. In addition, we discuss the emerging clinical evidence that N-BPs have a role in cancer immunotherapy.
Export Options
About this article
Cite this article as:
Clezardin P. and Massaia M., Nitrogen-Containing Bisphosphonates and Cancer Immunotherapy, Current Pharmaceutical Design 2010; 16 (27) . https://dx.doi.org/10.2174/138161210793563545
DOI https://dx.doi.org/10.2174/138161210793563545 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology
Current Molecular Medicine Pregnancy and Postpartum Influences on Rheumatoid Arthritis Activity:Natures Model to Investigate Systemic Biological Mechanisms in the Disease
Current Rheumatology Reviews Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Endocrinology and Immunology of Obesity, Obesity Vaccines
Current Clinical Pharmacology Activin Receptor-Like Kinase 1: a Novel Anti-angiogenesis Target from TGF-β Family
Mini-Reviews in Medicinal Chemistry Melanocortin Receptors as Drug Targets for Disorders of Energy Balance
CNS & Neurological Disorders - Drug Targets Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Human Carbonyl Reductases
Current Drug Metabolism Is Intake of Flavonoid-Based Food Supplements During Pregnancy Safe for the Developing Child? A Literature Review
Current Drug Targets Transfer of Biologically Important Molecules Between Cells Through Gap Junction Channels
Current Medicinal Chemistry Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism